Literature DB >> 21700686

Combining tricuspid valve repair with double lung transplantation in patients with severe pulmonary hypertension, tricuspid regurgitation, and right ventricular dysfunction.

Norihisa Shigemura1, Basar Sareyyupoglu2, Jay Bhama2, Pramod Bonde2, Jnanesh Thacker2, Christian Bermudez2, Cynthia Gries2, Maria Crespo2, Bruce Johnson2, Joseph Pilewski2, Yoshiya Toyoda2.   

Abstract

BACKGROUND: Concomitant tricuspid valve repair (TVR) and double lung transplantation (DLTx) has been a surgical option at our institution since 2004 in an attempt to improve the outcome of DLTx for end-stage pulmonary hypertension, severe tricuspid regurgitation, and right ventricle (RV) dysfunction. This study is a review of that single institutional experience.
METHODS: Consecutive cases of concomitant TVR and DLTx performed between 2004 and 2009 (TVR group, n = 20) were retrospectively compared with cases of DLTx alone for severe pulmonary hypertension without TVR (non-TVR group, n = 58).
RESULTS: There was one in-hospital death in the TVR group. The 90-day and 1- and 3-year survival rates for the TVR group were 90%, 75%, and 65%, respectively, which were not significantly different from those for the non-TVR group. The TVR group required less inotropic support and less prolonged mechanical ventilation in the ICU. Follow-up echocardiography demonstrated immediate elimination of both volume and pressure overload in the RV and tricuspid regurgitation in the TVR group. Notably, there was a significantly lower incidence of primary graft dysfunction following transplantation in the TVR group (P < .05). Pulmonary functional improvement shown by an FEV(1) increase after 6 months was also significantly better in the TVR group (40% vs 20%, P < .05).
CONCLUSIONS: Combined TVR and DLTx procedures were successfully performed without an increase in morbidity or mortality and contributed to decreased primary graft dysfunction. In our experience, this combined operative approach achieves clinical outcomes equal or superior to the outcomes seen in DLTx patients without RV dysfunction and severe tricuspid regurgitation.

Entities:  

Mesh:

Year:  2011        PMID: 21700686      PMCID: PMC4694149          DOI: 10.1378/chest.10-2929

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  21 in total

1.  Frequency and severity of tricuspid regurgitation determined by Doppler echocardiography in primary pulmonary hypertension.

Authors:  Alan L Hinderliter; Park W Willis; Walker A Long; William R Clarke; David Ralph; Edgar J Caldwell; William Williams; Neil A Ettinger; Nicholas S Hill; Warren R Summer; Bennett de Boisblanc; Gary Koch; Shu Li; Linda M Clayton; Maria M Jöbsis; James W Crow
Journal:  Am J Cardiol       Date:  2003-04-15       Impact factor: 2.778

2.  Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography.

Authors:  Lawrence G Rudski; Wyman W Lai; Jonathan Afilalo; Lanqi Hua; Mark D Handschumacher; Krishnaswamy Chandrasekaran; Scott D Solomon; Eric K Louie; Nelson B Schiller
Journal:  J Am Soc Echocardiogr       Date:  2010-07       Impact factor: 5.251

3.  Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation.

Authors:  Jason D Christie; Martin Carby; Remzi Bag; Paul Corris; Marshall Hertz; David Weill
Journal:  J Heart Lung Transplant       Date:  2005-06-04       Impact factor: 10.247

4.  Pulmonary arterial hypertension and lung transplantation.

Authors:  Rajeev Saggar; Joseph P Lynch; John A Belperio; S Samuel Weigt; Ariss Derhovanessian; Sachin Gupta; Rajan Saggar
Journal:  Semin Respir Crit Care Med       Date:  2010-03-30       Impact factor: 3.119

5.  The Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Lung and Heart-Lung Transplantation Report-2009.

Authors:  Jason D Christie; Leah B Edwards; Paul Aurora; Fabienne Dobbels; Richard Kirk; Axel O Rahmel; Josef Stehlik; David O Taylor; Anna Y Kucheryavaya; Marshall I Hertz
Journal:  J Heart Lung Transplant       Date:  2009-10       Impact factor: 10.247

6.  Single- versus double-lung transplantation for pulmonary hypertension.

Authors:  J S Gammie; R J Keenan; S M Pham; M F McGrath; B G Hattler; E Khoshbin; B P Griffith
Journal:  J Thorac Cardiovasc Surg       Date:  1998-02       Impact factor: 5.209

7.  Cardiac arrest in infants after congenital heart surgery.

Authors:  J F Rhodes; A D Blaufox; H S Seiden; J D Asnes; R P Gross; J P Rhodes; R B Griepp; A F Rossi
Journal:  Circulation       Date:  1999-11-09       Impact factor: 29.690

8.  Cardiac procedures in lung transplant recipients do not increase mortality in selected patients.

Authors:  Scott B Johnson; Anna M Allred; Adam M Cline; Luis F Angel; Edward Y Sako; Clinton E Baisden; John H Calhoon
Journal:  Ann Thorac Surg       Date:  2006-08       Impact factor: 4.330

9.  Severe left ventricular failure after double lung transplantation: pathophysiology and management.

Authors:  M Kamler; U Herold; J Piotrowski; T Bartel; H Teschler; H Jakob
Journal:  J Heart Lung Transplant       Date:  2004-01       Impact factor: 10.247

10.  Indications for and results of single, bilateral, and heart-lung transplantation for pulmonary hypertension.

Authors:  K Bando; J M Armitage; I L Paradis; R J Keenan; R L Hardesty; H Konishi; K Komatsu; K L Stein; A N Shah; H T Bahnson
Journal:  J Thorac Cardiovasc Surg       Date:  1994-12       Impact factor: 5.209

View more
  1 in total

Review 1.  Double-lung versus heart-lung transplantation for end-stage cardiopulmonary disease: a systematic review and meta-analysis.

Authors:  Hao-Ji Yan; Xiang-Yun Zheng; Heng Huang; Lin Xu; Hong-Tao Tang; Jun-Jie Wang; Cai-Han Li; Sheng-Xuan Zhang; Si-Yi Fu; Hong-Ying Wen; Dong Tian
Journal:  Surg Today       Date:  2022-09-06       Impact factor: 2.540

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.